GE HealthCare stock steadies on 2026 guidance and margin progress

GE HealthCare Technologies Inc. (US36266G1076) is shaped by its 2026 outlook, second-quarter 2026 operating trends and the companys latest reported revenue base, even as the shares continue to trade against broader health-care equipment sentiment. The latest published numbers include 2025 revenue of $19.7 billion, adjusted EPS of $4.50 in 2025 and a 2026 adjusted EPS outlook of $4.51 to $4.63, which gives investors a clear benchmark for the next reporting step.

2026 guidance sets the frame

The companys 2026 adjusted EPS range of $4.51 to $4.63 implies modest growth from 2025 adjusted EPS of $4.50, while 2025 revenue of $19.7 billion shows the scale of the installed base and service mix behind the stock. In the same latest reporting context, GE HealthCare also pointed to its 2026 free cash flow expectation of $1.6 billion to $1.8 billion, a number that matters because cash generation is often the key valuation driver for mature medtech businesses.

That guidance is more useful than a simple headline reaction because it links earnings, cash flow and the companys ability to fund capital returns. For market readers, the comparison between 2025 adjusted EPS of $4.50 and the 2026 range of $4.51 to $4.63 is small in percentage terms, but it still frames expectations around execution rather than expansion.

Revenue base and margins

GE HealthCare reported 2025 revenue of $19.7 billion, and that figure gives context to any move in the share price because the company is not a small cyclical name but a global equipment and imaging franchise. Its 2025 adjusted EPS of $4.50 also matters as a reference point for margin discipline, especially when paired with the 2026 free cash flow target of $1.6 billion to $1.8 billion.

The operating mix remains the central question for 2026 because even a limited increase in adjusted EPS can be meaningful when cash conversion is strong. A company that keeps revenue near $19.7 billion while protecting cash flow tends to trade on execution visibility rather than on headline growth alone.

What the market is pricing

As of the latest available market context, GE HealthCare stock is being judged against those published 2026 targets rather than against a pure short-term catalyst. The stock narrative is therefore built around whether the company can deliver EPS inside the $4.51 to $4.63 range while staying close to the $1.6 billion to $1.8 billion free cash flow band.

That setup is straightforward for investors to model because the key numbers are already visible: 2025 revenue of $19.7 billion, 2025 adjusted EPS of $4.50 and 2026 free cash flow guidance of $1.6 billion to $1.8 billion. The next report will mainly test whether those guideposts hold or need revision.

Imaging keeps the mix relevant

GE HealthCares imaging and diagnostic systems are the clearest product lens for the stock because the company still leans on large installed equipment bases and recurring service demand. That product mix helps explain why revenue scale and cash flow guidance matter more than a single-quarter headline.

For investors, the product detail matters only insofar as it supports the numbers: a $19.7 billion revenue base in 2025, adjusted EPS of $4.50 in 2025 and free cash flow guidance of $1.6 billion to $1.8 billion in 2026. Those figures are the practical frame for the shares.

Stock level to watch

GE HealthCare stock is best read through the same lens as its latest reported and guided numbers, not through a speculative story. The companys next earnings date and any refreshed outlook will matter because they will either confirm or narrow the 2026 EPS and cash flow ranges already on the table.